Impact Biomedical (IBO) Restructuring Costs (2022 - 2023)
Impact Biomedical's (IBO) quarterly Restructuring Costs came in at $122000.0 in Q4 2023, up 335.71% YoY from $28000.0 in Q4 2022, and up 430.43% on a QoQ basis from $23000.0 in Q3 2023.
Impact Biomedical (IBO) Restructuring Costs (2022 - 2023) Analysis & Trends
Impact Biomedical (IBO) has 2 years of Restructuring Costs data on file, last reported at $122000.0 in Q4 2023.
- Quarterly Restructuring Costs rose 335.71% year-over-year to $122000.0 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $187000.0 (changed N/A YoY) and the FY2023 annual result came in at $184000.0, up 170.59% from the prior year.
- Restructuring Costs climbed to $122000.0 in Q4 2023, from $23000.0 in the prior quarter.
- In the past five years, Restructuring Costs ranged from a high of $122000.0 in Q4 2023 to a low of $7000.0 in Q3 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Impact Biomedical | 49.45 Mn | 49.44 Mn | 2,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 122,000.00 |
| Sep 30, 2023 | 23,000.00 |
| Jun 30, 2023 | 14,000.00 |
| Dec 31, 2022 | 28,000.00 |
| Sep 30, 2022 | 7,000.00 |
| Jun 30, 2022 | 29,000.00 |